{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:55:49Z","timestamp":1793850949064,"version":"4.6.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82473724"],"award-info":[{"award-number":["82473724"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273730"],"award-info":[{"award-number":["82273730"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Science and Technology Major Project","award":["ZD2021CY001"],"award-info":[{"award-number":["ZD2021CY001"]}]},{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"crossref","award":["22ZR1414900"],"award-info":[{"award-number":["22ZR1414900"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Three-Year Public Health Action Plan of Shanghai","award":["GWVI-11.2-XD10"],"award-info":[{"award-number":["GWVI-11.2-XD10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-03034-7","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:54:01Z","timestamp":1765713241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Proteomic signature of metabolic dysfunction-associated steatotic liver disease and risk of atherosclerotic cardiovascular disease"],"prefix":"10.1186","volume":"25","author":[{"given":"Lulu","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyou","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"issue":"2","key":"3034_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","volume":"13","author":"N Stefan","year":"2025","unstructured":"Stefan N, Yki-Jarvinen H, Neuschwander-Tetri BA. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2025;13(2):134\u201348.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"3034_CR2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2468-1253(24)00310-8","volume":"10","author":"JJ Gries","year":"2025","unstructured":"Gries JJ, et al. Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease. Lancet Gastroenterol Hepatol. 2025;10(1):82\u201394.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3034_CR3","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","volume":"65","author":"JH Moon","year":"2023","unstructured":"Moon JH, et al. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine. 2023;65:102292.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"3034_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee HH, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73(3):533\u201340.","journal-title":"Gut"},{"issue":"1","key":"3034_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12916-024-03366-3","volume":"22","author":"AL Mayen","year":"2024","unstructured":"Mayen AL, et al. Hepatic steatosis, metabolic dysfunction and risk of mortality: findings from a multinational prospective cohort study. BMC Med. 2024;22(1):221.","journal-title":"BMC Med"},{"issue":"1","key":"3034_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12933-025-02824-3","volume":"24","author":"E Han","year":"2025","unstructured":"Han E, et al. Association of temporal MASLD with type 2 diabetes, cardiovascular disease and mortality. Cardiovasc Diabetol. 2025;24(1):289.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"3034_CR7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the, L","year":"2016","unstructured":"European Association for the Study of the, L. European association for the study of, and O. European association for the study of, EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u2013402.","journal-title":"J Hepatol"},{"issue":"5","key":"3034_CR8","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"key":"3034_CR9","doi-asserted-by":"crossref","unstructured":"Bourganou MV et al. Unraveling metabolic dysfunction-associated steatotic liver disease through the use of omics technologies. Int J Mol Sci. 2025;26(4).","DOI":"10.3390\/ijms26041589"},{"key":"3034_CR10","doi-asserted-by":"publisher","first-page":"1433857","DOI":"10.3389\/fcell.2024.1433857","volume":"12","author":"R Sandireddy","year":"2024","unstructured":"Sandireddy R, et al. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol. 2024;12:1433857.","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"3034_CR11","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41588-022-01199-5","volume":"54","author":"G Sveinbjornsson","year":"2022","unstructured":"Sveinbjornsson G, et al. Multiomics study of nonalcoholic fatty liver disease. Nat Genet. 2022;54(11):1652\u201363.","journal-title":"Nat Genet"},{"issue":"772","key":"3034_CR12","doi-asserted-by":"publisher","first-page":"eadh9940","DOI":"10.1126\/scitranslmed.adh9940","volume":"16","author":"J Ding","year":"2024","unstructured":"Ding J, et al. Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population. Sci Transl Med. 2024;16(772):eadh9940.","journal-title":"Sci Transl Med"},{"issue":"4","key":"3034_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s42255-023-00775-1","volume":"5","author":"O Govaere","year":"2023","unstructured":"Govaere O, et al. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures. Nat Metab. 2023;5(4):572\u20138.","journal-title":"Nat Metab"},{"issue":"8","key":"3034_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jama.2023.13258","volume":"330","author":"H Helgason","year":"2023","unstructured":"Helgason H, et al. Evaluation of large-scale proteomics for prediction of cardiovascular events. JAMA. 2023;330(8):725\u201335.","journal-title":"JAMA"},{"issue":"18","key":"3034_CR15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/eurheartj\/ehad161","volume":"44","author":"NS Nurmohamed","year":"2023","unstructured":"Nurmohamed NS, et al. Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction. Eur Heart J. 2023;44(18):1594\u2013607.","journal-title":"Eur Heart J"},{"issue":"10","key":"3034_CR16","doi-asserted-by":"publisher","first-page":"102230","DOI":"10.1016\/j.clinre.2023.102230","volume":"47","author":"X Zhang","year":"2023","unstructured":"Zhang X, Li X, Xiong X. Applying proteomics in metabolic dysfunction-associated steatotic liver disease: from mechanism to biomarkers. Clin Res Hepatol Gastroenterol. 2023;47(10):102230.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"3034_CR17","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.diabet.2023.101506","volume":"50","author":"J Bilson","year":"2024","unstructured":"Bilson J, et al. Steatotic liver disease, MASLD and risk of chronic kidney disease. Diabetes Metab. 2024;50(1):101506.","journal-title":"Diabetes Metab"},{"issue":"729","key":"3034_CR18","doi-asserted-by":"publisher","first-page":"eadf4428","DOI":"10.1126\/scitranslmed.adf4428","volume":"16","author":"NE Allen","year":"2024","unstructured":"Allen NE, et al. Prospective study design and data analysis in UK biobank. Sci Transl Med. 2024;16(729):eadf4428.","journal-title":"Sci Transl Med"},{"issue":"3","key":"3034_CR19","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779.","journal-title":"PLoS Med"},{"issue":"7982","key":"3034_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","volume":"622","author":"GH Eldjarn","year":"2023","unstructured":"Eldjarn GH, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622(7982):348\u201358.","journal-title":"Nature"},{"key":"3034_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.","journal-title":"BMC Gastroenterol"},{"key":"3034_CR22","doi-asserted-by":"crossref","unstructured":"Zeng H et al. Prognostic and predictive effects of new steatotic liver disease nomenclatures: a large population-based study. MedComm (2020). 2025;6(2):e70087.","DOI":"10.1002\/mco2.70087"},{"key":"3034_CR23","doi-asserted-by":"publisher","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"HJ Choe","year":"2024","unstructured":"Choe HJ, et al. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism. 2024;153:155800.","journal-title":"Metabolism"},{"issue":"4","key":"3034_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/sim.4067","volume":"30","author":"IR White","year":"2011","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377\u201399.","journal-title":"Stat Med"},{"issue":"7982","key":"3034_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, et al. Plasma proteomic associations with genetics and health in the UK biobank. Nature. 2023;622(7982):329\u201338.","journal-title":"Nature"},{"issue":"8","key":"3034_CR26","doi-asserted-by":"publisher","first-page":"e14195","DOI":"10.1111\/acel.14195","volume":"23","author":"CL Kuo","year":"2024","unstructured":"Kuo CL, et al. Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults. Aging Cell. 2024;23(8):e14195.","journal-title":"Aging Cell"},{"issue":"28","key":"3034_CR27","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/eurheartj\/ehaa209","volume":"41","author":"J Li","year":"2020","unstructured":"Li J, et al. The mediterranean diet, plasma metabolome, and cardiovascular disease risk. Eur Heart J. 2020;41(28):2645\u201356.","journal-title":"Eur Heart J"},{"issue":"1","key":"3034_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ije\/dyr233","volume":"41","author":"CL Relton","year":"2012","unstructured":"Relton CL, Davey Smith G. Two-step epigenetic Mendelian randomization: a strategy for establishing the causal role of epigenetic processes in pathways to disease. Int J Epidemiol. 2012;41(1):161\u201376.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"3034_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, et al. Detection of widespread horizontal Pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"3034_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1186\/s12967-024-05478-z","volume":"22","author":"L Xiao","year":"2024","unstructured":"Xiao L, et al. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes. J Transl Med. 2024;22(1):650.","journal-title":"J Transl Med"},{"issue":"12","key":"3034_CR31","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad E, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53(12):1712\u201321.","journal-title":"Nat Genet"},{"issue":"D1","key":"3034_CR32","doi-asserted-by":"publisher","first-page":"D1227","DOI":"10.1093\/nar\/gkad1040","volume":"52","author":"M Cannon","year":"2024","unstructured":"Cannon M, et al. DGIdb 5.0: rebuilding the drug-gene interaction database for precision medicine and drug discovery platforms. Nucleic Acids Res. 2024;52(D1):D1227\u201335.","journal-title":"Nucleic Acids Res"},{"key":"3034_CR33","unstructured":"Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. Adv Neural Inf Process Syst. 2017;30."},{"issue":"5","key":"3034_CR34","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ejendo\/lvaf103","volume":"192","author":"J Wu","year":"2025","unstructured":"Wu J, et al. Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases. Eur J Endocrinol. 2025;192(5):691\u2013703.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"3034_CR35","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams LA, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138\u201353.","journal-title":"Gut"},{"issue":"9735","key":"3034_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","volume":"376","author":"MJ O\u2019Donnell","year":"2010","unstructured":"O\u2019Donnell MJ, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376(9735):112\u201323.","journal-title":"Lancet"},{"key":"3034_CR37","doi-asserted-by":"crossref","unstructured":"Eriksson MB, Eriksson LB, Larsson AO. Significant interplay between lipids, cytokines, chemokines, growth factors, and blood cells in an outpatient cohort. Int J Mol Sci. 2025;26(16).","DOI":"10.3390\/ijms26167746"},{"issue":"7","key":"3034_CR38","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jacc.2016.11.065","volume":"69","author":"R Pechlaner","year":"2017","unstructured":"Pechlaner R, et al. Very-Low-Density Lipoprotein-Associated apolipoproteins predict cardiovascular events and are Lowered by Inhibition of APOC-III. J Am Coll Cardiol. 2017;69(7):789\u2013800.","journal-title":"J Am Coll Cardiol"},{"key":"3034_CR39","doi-asserted-by":"crossref","unstructured":"Sirca TB et al. The role of polyphenols in modulating PON1 activity regarding endothelial dysfunction and atherosclerosis. Int J Mol Sci. 2024;25(5).","DOI":"10.3390\/ijms25052962"},{"key":"3034_CR40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.freeradbiomed.2025.07.039","volume":"239","author":"Z Cui","year":"2025","unstructured":"Cui Z, et al. Serum Selenoprotein P concentrations and cardiovascular disease: results from a large, prospective cohort study of older German adults. Free Radic Biol Med. 2025;239:270\u20139.","journal-title":"Free Radic Biol Med"},{"key":"3034_CR41","doi-asserted-by":"crossref","unstructured":"Moreno-Vedia J et al. Unveiling the role of the fatty acid binding protein 4 in the metabolic-associated fatty liver disease. Biomedicines. 2022;10(1).","DOI":"10.3390\/biomedicines10010197"},{"issue":"5","key":"3034_CR42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11883-024-01196-5","volume":"26","author":"EM van der Ark-Vonk","year":"2024","unstructured":"van der Ark-Vonk EM, et al. The effects of FABP4 on cardiovascular disease in the aging population. Curr Atheroscler Rep. 2024;26(5):163\u201375.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"3034_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5551\/jat.48710","volume":"26","author":"M Furuhashi","year":"2019","unstructured":"Furuhashi M. Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. J Atheroscler Thromb. 2019;26(3):216\u201332.","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"3034_CR44","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41590-019-0479-x","volume":"20","author":"JT Barata","year":"2019","unstructured":"Barata JT, Durum SK, Seddon B. Flip the coin: IL-7 and IL-7R in health and disease. Nat Immunol. 2019;20(12):1584\u201393.","journal-title":"Nat Immunol"},{"issue":"1","key":"3034_CR45","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41467-025-56918-3","volume":"16","author":"MC Barbera","year":"2025","unstructured":"Barbera MC, et al. Increased ectodysplasin-A2-receptor EDA2R is a ubiquitous hallmark of aging and mediates parainflammatory responses. Nat Commun. 2025;16(1):1898.","journal-title":"Nat Commun"},{"issue":"4","key":"3034_CR46","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jhep.2016.12.004","volume":"66","author":"AK Kopec","year":"2017","unstructured":"Kopec AK, et al. Fibrin(ogen) drives repair after acetaminophen-induced liver injury via leukocyte alpha(M)beta(2) integrin-dependent upregulation of Mmp12. J Hepatol. 2017;66(4):787\u201397.","journal-title":"J Hepatol"},{"issue":"2","key":"3034_CR47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/JS9.0000000000000922","volume":"110","author":"X Zou","year":"2024","unstructured":"Zou X, et al. Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes: a multicenter Mendelian randomization study. Int J Surg. 2024;110(2):766\u201376.","journal-title":"Int J Surg"},{"issue":"3","key":"3034_CR48","doi-asserted-by":"publisher","first-page":"oead056","DOI":"10.1093\/ehjopen\/oead056","volume":"3","author":"S Yuan","year":"2023","unstructured":"Yuan S, et al. Circulating proteins and peripheral artery disease risk: observational and Mendelian randomization analyses. Eur Heart J Open. 2023;3(3):oead056.","journal-title":"Eur Heart J Open"},{"issue":"1","key":"3034_CR49","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1038\/s41467-025-58183-w","volume":"16","author":"H Xu","year":"2025","unstructured":"Xu H, et al. Targeting CCNE1 amplified ovarian and endometrial cancers by combined Inhibition of PKMYT1 and ATR. Nat Commun. 2025;16(1):3112.","journal-title":"Nat Commun"},{"issue":"26","key":"3034_CR50","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood.2023021088","volume":"143","author":"L Lenk","year":"2024","unstructured":"Lenk L, et al. The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood. 2024;143(26):2735\u201348.","journal-title":"Blood"},{"issue":"10","key":"3034_CR51","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.2337\/db21-0056","volume":"70","author":"EH Dahlstrom","year":"2021","unstructured":"Dahlstrom EH, et al. The Low-Expression variant of FABP4 is associated with cardiovascular disease in type 1 diabetes. Diabetes. 2021;70(10):2391\u2013401.","journal-title":"Diabetes"},{"issue":"1","key":"3034_CR52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/liv.14272","volume":"40","author":"G Sansoe","year":"2020","unstructured":"Sansoe G, Aragno M, Wong F. Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease. Liver Int. 2020;40(1):18\u201331.","journal-title":"Liver Int"},{"issue":"5","key":"3034_CR53","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s12072-016-9705-x","volume":"10","author":"G Kim","year":"2016","unstructured":"Kim G, et al. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int. 2016;10(5):819\u201328.","journal-title":"Hepatol Int"},{"key":"3034_CR54","doi-asserted-by":"crossref","unstructured":"Poznyak AV et al. Renin-Angiotensin system in pathogenesis of atherosclerosis and treatment of CVD. Int J Mol Sci. 2021;22(13).","DOI":"10.3390\/ijms22136702"},{"issue":"5","key":"3034_CR55","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1476-5381.1996.tb15277.x","volume":"117","author":"JP van Kats","year":"1996","unstructured":"van Kats JP, et al. Assessment of the role of the Renin-angiotensin system in cardiac contractility utilizing the Renin inhibitor Remikiren. Br J Pharmacol. 1996;117(5):891\u2013901.","journal-title":"Br J Pharmacol"},{"key":"3034_CR56","doi-asserted-by":"crossref","unstructured":"Gheorghe L et al. Risk scores for prediction of major cardiovascular events in non-alcoholic fatty liver disea0se: A no man\u2019s land? Life (Basel). 2023;13(4).","DOI":"10.3390\/life13040857"},{"key":"3034_CR57","doi-asserted-by":"publisher","first-page":"122745","DOI":"10.1016\/j.lfs.2024.122745","volume":"350","author":"M Cao","year":"2024","unstructured":"Cao M, Ke D, Zhou H. The role and molecular mechanism of CTHRC1 in fibrosis. Life Sci. 2024;350:122745.","journal-title":"Life Sci"},{"issue":"1","key":"3034_CR58","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12933-025-02865-8","volume":"24","author":"X Xie","year":"2025","unstructured":"Xie X, et al. Interpretable machine learning-guided single-cell mapping Deciphers multi-lineage pancreatic dysregulation in type 2 diabetes. Cardiovasc Diabetol. 2025;24(1):300.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"3034_CR59","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00125-022-05846-8","volume":"66","author":"H Maalmi","year":"2023","unstructured":"Maalmi H, et al. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy. Diabetologia. 2023;66(3):579\u201389.","journal-title":"Diabetologia"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03034-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03034-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03034-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T14:03:47Z","timestamp":1768917827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-03034-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03034-7","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the North West Multicenter Research Ethics Committee (11\/NW\/0382), and informed consent was provided by all participants (application number 98410).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}